Minimally invasive lobectomy with neoadjuvant targeted therapy: the Zhejiang Cancer Hospital experience.
作者信息
Luo Taobo, Zeng Jian
机构信息
Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China.
出版信息
J Thorac Dis. 2019 Jan;11(1):266-269. doi: 10.21037/jtd.2018.12.100.
Abstract
摘要
相似文献
1
Minimally invasive lobectomy with neoadjuvant targeted therapy: the Zhejiang Cancer Hospital experience.新辅助靶向治疗下的微创肺叶切除术：浙江省肿瘤医院的经验
J Thorac Dis. 2019 Jan;11(1):266-269. doi: 10.21037/jtd.2018.12.100.
2
Totally minimally invasive esophagectomy after neoadjuvant chemoradiotherapy: Long-term oncologic outcomes.新辅助放化疗后完全微创食管切除术：长期肿瘤学结局
J Surg Oncol. 2018 Mar;117(4):651-658. doi: 10.1002/jso.24935.
3
Minimally Invasive Lobectomy Modality and Other Predictors of Conversion to Thoracotomy.微创肺叶切除术方式及其他转为开胸手术的预测因素。
Innovations (Phila). 2019 Aug;14(4):342-352. doi: 10.1177/1556984519849037. Epub 2019 May 17.
4
Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity.新辅助放化疗后行杂交微创Ivor Lewis食管癌切除术可获得极佳的长期生存结果，且并发症极少。
J Surg Oncol. 2016 Dec;114(7):838-847. doi: 10.1002/jso.24409. Epub 2016 Aug 28.
5
Minimally invasive thyroid nodulectomy reduces post-operative hypothyroidism when compared with thyroid lobectomy.与甲状腺叶切除术相比，微创甲状腺结节切除术可降低术后甲状腺功能减退的发生率。
ANZ J Surg. 2017 May;87(5):360-363. doi: 10.1111/ans.12904. Epub 2014 Nov 13.
6
Readmissions After Lobectomy in an Era of Increasing Minimally Invasive Surgery: A Statewide Analysis.微创外科手术日益普及时代下肺叶切除术后再入院情况：一项全州范围的分析
Innovations (Phila). 2019 Oct;14(5):453-462. doi: 10.1177/1556984519874064. Epub 2019 Sep 18.
7
The variability of practice in minimally invasive thoracic surgery for pulmonary resections.肺切除微创手术的实践差异。
Thorac Surg Clin. 2008 Aug;18(3):235-47. doi: 10.1016/j.thorsurg.2008.06.002.
8
[Thoracoscopic lobectomy as minimally invasive surgery].[胸腔镜肺叶切除术作为微创手术]
Nihon Geka Gakkai Zasshi. 2014 May;115(3):143-6.
9
Reliability and safety of minimally invasive esophagectomy after neoadjuvant chemoradiation: a retrospective study.新辅助放化疗后微创食管切除术的可靠性和安全性：一项回顾性研究
J Cardiothorac Surg. 2019 May 28;14(1):97. doi: 10.1186/s13019-019-0920-0.
10
Transitioning from video-assisted thoracic surgical lobectomy to robotics for lung cancer: are there outcomes advantages?从电视辅助胸腔镜肺叶切除术到机器人手术治疗肺癌：是否有结果优势？
J Thorac Cardiovasc Surg. 2014 Feb;147(2):724-9. doi: 10.1016/j.jtcvs.2013.10.002. Epub 2013 Nov 16.
本文引用的文献
1
[A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].厄洛替尼与培美曲塞联合顺铂用于ⅢA期表皮生长因子受体突变型肺腺癌新辅助治疗的随机对照研究
Zhonghua Zhong Liu Za Zhi. 2018 Feb 23;40(2):133-137. doi: 10.3760/cma.j.issn.0253-3766.2018.02.010.
2
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.化疗和靶向治疗在早期非小细胞肺癌中的作用。
Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70. doi: 10.1080/14737140.2018.1409624. Epub 2017 Nov 26.
3
Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer.对于一名年轻的IIIA期非小细胞肺癌患者，在常规化疗无效时，克唑替尼作为新辅助治疗的非标签使用情况。
Am J Case Rep. 2017 Aug 15;18:890-893. doi: 10.12659/ajcr.903528.
4
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.大细胞神经内分泌癌转化和EGFR-T790M突变作为肺癌中EGFR-TKI获得性耐药的共存机制
Mayo Clin Proc. 2017 Aug;92(8):1304-1311. doi: 10.1016/j.mayocp.2017.03.022.
5
Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation.厄洛替尼、卡铂、培美曲塞和贝伐单抗用于初治的伴有表皮生长因子受体突变的晚期非鳞状非小细胞肺癌患者的Ⅰ/Ⅱ期研究
Genes Cancer. 2017 May;8(5-6):559-565. doi: 10.18632/genesandcancer.145.
6
[Efficacy and Potential Application of Neoadjuvant Chemotherapy in Patients with IIIa Stage Non-small Cell Lung Cancer].新辅助化疗在Ⅲa期非小细胞肺癌患者中的疗效及潜在应用
Zhongguo Fei Ai Za Zhi. 2017 Feb 20;20(2):100-106. doi: 10.3779/j.issn.1009-3419.2017.02.04.
7
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.肺癌的新辅助和辅助表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗。
Transl Lung Cancer Res. 2015 Feb;4(1):82-93. doi: 10.3978/j.issn.2218-6751.2014.11.08.
8
9
Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.早期非小细胞肺癌患者新辅助厄洛替尼的肿瘤反应和毒性。
J Clin Oncol. 2012 Aug 1;30(22):2731-8. doi: 10.1200/JCO.2011.39.4882. Epub 2012 Jul 2.
10
PET/CT in the staging of the non-small-cell lung cancer.PET/CT在非小细胞肺癌分期中的应用
J Biomed Biotechnol. 2012;2012:783739. doi: 10.1155/2012/783739. Epub 2012 Mar 7.
Zotero 插件